Results 221 to 230 of about 188,307 (314)

The impact of decreased left ventricular ejection fraction on neutrophil extracellular trap (NET) formation measured by citrullinated histone H3 (citH_3) concentration. [PDF]

Sci Rep
Urbanowicz T, Krasińska B, Spasenenko I, Gabriel K, Dziatkiewicz-Warkocz P, Mertowski S, Bojarski K, Grywalska E, Filipiak K, Tykarski A, Krasiński Z, Jemielity M, Gil L, Rupa-Matysek J.   +13 more
europepmc   +1 more source

Impact of centrifugal-flow left ventricular assist device implantation on the disease course, functional class, and quality of life in patients with end-stage heart failure with reduced ejection fraction. A 6-month follow-up experience

Janna A. Shahramanova, O. Yu. Narusov, V. A. Amanatova, Yu. F. Osmolovskaya, K. G. Ganaev, A.A. Shiryaev, Р.С. Акчурин, I. A. Merkulova, Д. В. Певзнер, М. А. Саидова, С. Н. Терещенко   +10 more
openalex   +2 more sources

Untangling the prognostic value of diastolic dysfunction, NT-proBNP, and frailty in older patients with preserved left ventricular ejection fraction without valvular disease. [PDF]

BMC Geriatr
de Terwangne C, Vaes B, Pasquet A, Boland B, Pouleur AC, Degryse JM.   +5 more
europepmc   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Outcomes and Left Ventricular Ejection Fraction in Cardiac Magnetic Resonance: Challenging the "Higher Is Better". [PDF]

J Am Heart Assoc
Krittayaphong R, Songsangjinda T, Jirataiporn K, Yindeengam A.   +3 more
europepmc   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Ventricular Tachycardia Ablation in Patients With Severely Decreased Left Ventricular Ejection Fraction. [PDF]

J Cardiovasc Electrophysiol
Ghannam M, Christian-Miller N, Liang J, Deshmukh A, Arps K, Latchamsetty R, Crawford T, Jongnarangsin K, Oral H, Morady F, Bogun F.   +10 more
europepmc   +1 more source

Outcomes From Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis and Left Ventricular Ejection Fraction Less Than 30%

, 2018
Frédéric Maes, Stamatios Lerakis, Henrique Barbosa Ribeiro, Martine Gilard, João L. Cavalcante, Raj Makkar, Hartmut Herrmann, Stephan Windecker, Maurice Enriquez‐Sarano, Asim N. Cheema, Luis Nombela‐Franco, Ignacio J. Amat‐Santos, Antonio J. Muñoz-García, Bruno García del Blanco, Alan Zajarías, John Lisko, Salim S. Hayek, Vasilis Babaliaros, Florent Le Ven, Thomas G. Gleason, Tarun Chakravarty, Wilson Y. Szeto, Marie‐Annick Clavel, José Agustín, Violeta Serra, John Schindler, Abdellaziz Dahou, Mohamed‐Salah Annabi, Émilie Pelletier-Beaumont, Mélanie Côté, Rishi Puri, Philippe Pîbarot, Josep Rodés‐Cabau   +32 more
openalex   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source